Crescent Biopharma (CBIO) Stock Analysis

What Crescent Biopharma does

Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.

Key metrics

ETFs linked to CBIO

Broad-market and Healthcare sector ETFs an investor holding Crescent Biopharma is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CBIO fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Crescent Biopharma?

Crescent Biopharma trades under the ticker CBIO on NASDAQ.

Which exchange is CBIO listed on?

CBIO is listed on NASDAQ.

What sector does Crescent Biopharma operate in?

Crescent Biopharma is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CBIO in a portfolio?

PortView shows CBIO's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.